drugset / Trial / NCT01929499

Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer

NCT01929499

Phase 2 Unknown 210 enrolled Yanjuan Zhu
RandomizedParallel-groupOpen-labelTreatment

Summary

It has been reported that the immune status of patients with cancer were suppressed, especially those after surgery and adjuvant chemotherapy. Thus, immunotherapy may decrease the recurrence rate after surgery. CIK cells transfusion has been reported as an effect therapy in advanced cancers. In another retrospective study, investigators found that adjuvant CIK therapy would prolong the disease-free survival (DFS) for colorectal cancer patients. The purpose of this study is to determine wether adjuvant immunotherapy with CIK cells in patients with colon cancer after operation will prolong DFS, and overall survival (OS).

Timeline

Start
2013-09
Primary completion
2016-08
Completion
2019-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CIK cells Cell therapy 3e+09 cells Other

Indications